Pharmala Biotech Holdings Inc. (MDMA.CN)
CAD 0.17
(10.0%)
CAD 0.17
(10.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -710.18 Thousand CAD | 28.78% |
| 2022 | -973.44 Thousand CAD | 61.2% |
| 2021 | -2.5 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -206.79 Thousand CAD | -193.28% |
| 2024 Q1 | 221.69 Thousand CAD | 116.87% |
| 2024 Q3 | -397.37 Thousand CAD | -92.16% |
| 2023 Q2 | -204.71 Thousand CAD | 25.65% |
| 2023 Q1 | -275.32 Thousand CAD | -52.57% |
| 2023 Q3 | -325.56 Thousand CAD | -59.04% |
| 2023 FY | - CAD | 28.78% |
| 2023 Q4 | 102.22 Thousand CAD | 131.4% |
| 2022 Q2 | -284.88 Thousand CAD | 5.81% |
| 2022 Q1 | -302.46 Thousand CAD | 0.0% |
| 2022 Q3 | -205.63 Thousand CAD | 27.82% |
| 2022 FY | - CAD | 61.2% |
| 2022 Q4 | -180.45 Thousand CAD | 12.24% |
| 2021 Q3 | -2.31 Million CAD | 0.0% |
| 2021 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 85.743% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 91.271% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 77.747% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 90.762% |
| ChitogenX Inc. | -2.69 Million CAD | 73.638% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | 76.521% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 94.397% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 5175.288% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 86.279% |
| Glow Lifetech Corp. | -1.26 Million CAD | 43.772% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -9.542% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -122.295% |
| MYND Life Sciences Inc. | -1.82 Million CAD | 61.09% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | 40.931% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 76.665% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | 25.642% |
| Telescope Innovations Corp. | -5.49 Million CAD | 87.065% |